U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H18N8O5
Molecular Weight 390.354
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of REGADENOSON ANHYDROUS

SMILES

CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2

InChI

InChIKey=LZPZPHGJDAGEJZ-AKAIJSEGSA-N
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html

Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
LEXISCAN

Approved Use

Lexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress (1).

Launch Date

2008
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
13.6 ng/mL
400 μg single, intravenous
dose: 400 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
REGADENOSON plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.7 ng × h/mL
400 μg single, intravenous
dose: 400 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
REGADENOSON plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
400 μg single, intravenous
dose: 400 μg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
REGADENOSON plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (3 patients)
Flushing (3 patients)
Shortness of breath (4 patients)
Nausea and vomiting (5 patients)
Change in ECG (1 patient)
Headache (4 patients)
Sources: Page: 1211
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (3 patients)
Dizziness (3 patients)
Shortness of breath (1 patient)
Nausea and vomiting (2 patients)
Headache (3 patients)
Sources: Page: 1211
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Palpitation, Dizziness...
Other AEs:
Palpitation (4 patients)
Dizziness (2 patients)
Flushing (4 patients)
Shortness of breath (2 patients)
Change in ECG (1 patient)
Headache (1 patient)
Sources: Page: 1211
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (2 patients)
Palpitation (2 patients)
Dizziness (3 patients)
Flushing (1 patient)
Nausea and vomiting (4 patients)
Headache (3 patients)
Sources: Page: 1211
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (4 patients)
Dizziness (3 patients)
Flushing (8 patients)
Shortness of breath (3 patients)
Nausea and vomiting (3 patients)
Change in ECG (7 patients)
Headache (7 patients)
Sources: Page: 1211
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Palpitation, Dizziness...
Other AEs:
Palpitation (2 patients)
Dizziness (1 patient)
Flushing (1 patient)
Change in ECG (3 patients)
Sources: Page: 1211
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Other AEs: Chest pain, Palpitation...
Other AEs:
Chest pain (1 patient)
Palpitation (2 patients)
Dizziness (1 patient)
Flushing (3 patients)
Shortness of breath (1 patient)
Change in ECG (1 patient)
Sources: Page: 1211
AEs

AEs

AESignificanceDosePopulation
Change in ECG 1 patient
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 3 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 3 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 4 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 4 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 5 patients
30 ug/kg single, intravenous
Highest studied dose
Dose: 30 ug/kg
Route: intravenous
Route: single
Dose: 30 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 2 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 3 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 3 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 3 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 1 patient
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 2 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 2 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 4 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 4 patients
10 ug/kg single, intravenous
MTD
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 1 patient
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 2 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 2 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 4 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Nausea and vomiting 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 3 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 4 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 7 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Headache 7 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 8 patients
20 ug/kg single, intravenous
MTD
Dose: 20 ug/kg
Route: intravenous
Route: single
Dose: 20 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 2 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 3 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in standing position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Change in ECG 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Chest pain 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Dizziness 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Shortness of breath 1 patient
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Palpitation 2 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Flushing 3 patients
3 ug/kg single, intravenous
Recommended
Dose: 3 ug/kg
Route: intravenous
Route: single
Dose: 3 ug/kg
Sources: Page: 1211
healthy, 18-50 years
n = 4
Health Status: healthy
Condition: in supine position
Age Group: 18-50 years
Sex: M
Population Size: 4
Sources: Page: 1211
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim

Drug as victim

Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Adenosine receptors as therapeutic targets.
2006 Mar
Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.
2007 Jul
New stress test agents reduce adverse effects.
2008 May 14
Selective adenosine agonists and myocardial perfusion imaging.
2012 Feb
Patents

Sample Use Guides

In Vivo Use Guide
5 mL (0.4 mg) by rapid injection; followed immediately by saline flush and radiopharmaceutical.
Route of Administration: Intravenous
10 nM CVT-3146 decreased coronary perfusion pressure by 23 mm Hg in rat isolated perfused heart.
Name Type Language
REGADENOSON ANHYDROUS
Common Name English
regadenoson [INN]
Common Name English
REGADENOSON [MART.]
Common Name English
REGADENOSON [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000178375
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
WHO-ATC C01EB21
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
Code System Code Type Description
RXCUI
1546015
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY RxNorm
FDA UNII
7AXV542LZ4
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
PUBCHEM
219024
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
DAILYMED
7AXV542LZ4
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
NCI_THESAURUS
C171933
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
MERCK INDEX
m9517
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY Merck Index
EVMPD
SUB30494
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
EPA CompTox
DTXSID4057712
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
CAS
313348-27-5
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
INN
8488
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY
DRUG BANK
DB06213
Created by admin on Fri Dec 15 15:34:22 GMT 2023 , Edited by admin on Fri Dec 15 15:34:22 GMT 2023
PRIMARY